(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors
Uno studio clinico di fase 3 randomizzato, in aperto, multicentrico di CGT9486+Sunitinib rispetto a Sunitinib in soggetti con tumori stromali gastrointestinali localmente avanzati, non resecabili o metastatici
This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450 (CYP)3A4 inducer in approximately 16 participants who have received at least one prior line of therapy for GIST and 2) a substudy intended to test the efficacy of bezuclastinib and sunitinib as first-line (1L) treatment of GIST in approximately 40 participants with KIT exon 9 mutations and no prior systemic therapy (with the exception of up to 10 participants with ongoing imatinib therapy of ≤4 weeks).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Cogent Biosciences
- Numero di telefono: 617-945-5576
- Email: peakinfo@cogentbio.com
Luoghi di studio
-
-
-
Buenos Aires, Argentina, C1426ANZ
- Attivo, non reclutante
- Instituto Alexander Fleming
-
Córdoba, Argentina, X5000HWE
- Attivo, non reclutante
- Instituto Oncologico de Cordoba (IONC)
-
-
-
-
-
Bankstown, Australia, 2200
- Attivo, non reclutante
- Bankstown-Lidcombe Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Attivo, non reclutante
- Sir Charles Gairdner Hospital
-
-
-
-
-
Campinas, Brasile, 130.83-888
- Attivo, non reclutante
- Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)
-
Rio de Janeiro, Brasile, 20.230-130
- Attivo, non reclutante
- lnstituto Nacional de Cancer - INCA
-
São Paulo, Brasile, 09060-650
- Attivo, non reclutante
- CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
-
-
-
-
-
Calgary, Canada, T2N 4N2
- Reclutamento
- Tom Baker Cancer Center
-
Montreal, Canada, HIT 2M4
- Attivo, non reclutante
- Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR)
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Reclutamento
- Alberta Health Services Cross Cancer Institute
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Reclutamento
- Princess Margaret Hospital
-
-
-
-
-
Brno, Cechia, 65653
- Attivo, non reclutante
- Masarykuv onkologicky ustav
-
Hradec Králové, Cechia, 500 05
- Ritirato
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Cechia, 77900
- Attivo, non reclutante
- Fakultni nemocnice Olomouc - Oncology clinic
-
-
-
-
-
Santiago, Chile, 7500921
- Attivo, non reclutante
- Instituto Oncologico FALP
-
Santiago, Chile, 7560908
- Attivo, non reclutante
- Centro de Oncologia de Precision, Universidad Mayor
-
-
-
-
-
Seoul, Corea del Sud, 03080
- Attivo, non reclutante
- Seoul National University Hospital
-
Seoul, Corea del Sud, 06351
- Attivo, non reclutante
- Samsung Medical Center
-
Seoul, Corea del Sud, 08308
- Attivo, non reclutante
- Korea University Guro Hospital
-
Seoul, Corea del Sud, 05505
- Attivo, non reclutante
- Asan Medical Center
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Corea del Sud, 10408
- Ritirato
- National Cancer Center
-
-
-
-
-
Aarhus, Danimarca, 8200
- Attivo, non reclutante
- Aarhus University Hospital
-
-
-
-
-
Bordeaux, Francia, 33076
- Attivo, non reclutante
- Institut Bergonie
-
Lille, Francia, 59000
- Attivo, non reclutante
- Centre Oscar Lambret
-
Lyon, Francia, 69008
- Attivo, non reclutante
- Centre Leon Berard
-
Marseille, Francia, 13005
- Attivo, non reclutante
- AP-HM - Hôpital de la Timone
-
Rennes, Francia, 35042
- Attivo, non reclutante
- Centre Eugene Marquis
-
Saint-Herblain, Francia, 44800
- Attivo, non reclutante
- ICO St-Herblain
-
Toulouse, Francia, 31400
- Attivo, non reclutante
- CHU de Toulouse - Hospital Rangueil
-
Villejuif, Francia, 94805
- Attivo, non reclutante
- Gustave Roussy
-
-
-
-
-
Bad Saarow, Germania, 15526
- Attivo, non reclutante
- Helios Klinikum Bad Saarow
-
Berlin, Germania, 13125
- Attivo, non reclutante
- Helios Klinikum Berlin-Buch
-
Essen, Germania, 45147
- Attivo, non reclutante
- Universitaetsklinikum Essen
-
Hamburg, Germania, 20246
- Attivo, non reclutante
- Universitaetsklinikum Hamburg-Eppendorf
-
Hanover, Germania, 30625
- Attivo, non reclutante
- Medizinische Hochschule Hannover- Urology Oncology
-
Mannheim, Germania, 68167
- Attivo, non reclutante
- Universitaetsmedizin Mannheim
-
-
-
-
-
Central, Hong Kong
- Ritirato
- Humanity & Health Clinical Trial Centre
-
Jordon, Hong Kong
- Attivo, non reclutante
- Hong Kong United Oncology Centre
-
Shatin, Hong Kong
- Attivo, non reclutante
- Prince of Wales Hospital
-
-
-
-
-
Aviano, Italia, 33081
- Attivo, non reclutante
- Centro Riferimento Oncologico - Aviano
-
Bologna, Italia, 40138
- Attivo, non reclutante
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
-
Brescia, Italia, 25123
- Attivo, non reclutante
- ASST degli Spedali Civili di Brescia
-
Candiolo, Italia, 10060
- Ritirato
- IRCCS La Fondazione e l'Istituto di Candiolo
-
Florence, Italia, 50134
- Attivo, non reclutante
- Azienda Ospedaliero-Universitaria Careggi
-
Meldola, Italia, 47014
- Attivo, non reclutante
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
-
Milan, Italia, 20133
- Attivo, non reclutante
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan, Italia, 20141
- Attivo, non reclutante
- Istituto Europeo di Oncologia
-
Palermo, Italia, 90127
- Attivo, non reclutante
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
-
Roma, Italia, 00128
- Attivo, non reclutante
- Policlinico Universitario Campus Bio-Medico
-
Rozzano, Italia, 20089
- Attivo, non reclutante
- Istituto Clinico Humanitas
-
Verona, Italia, 31726
- Attivo, non reclutante
- Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
-
-
-
-
-
Aguascalientes, Messico, 20116
- Ritirato
- Centro de Investigacion Medica Aquascalientes (CIMA)
-
Monterrey, Messico, 64710
- Attivo, non reclutante
- I Can Oncology Center SA De CV
-
Oaxaca City, Messico, 68000
- Ritirato
- Oaxaca Site Management Organization S.C.
-
-
-
-
-
Bergen, Norvegia, 5021
- Attivo, non reclutante
- Haukeland University Hospital - Bergen
-
Oslo, Norvegia, 0310
- Attivo, non reclutante
- Oslo University Hospital
-
-
-
-
-
Amsterdam, Olanda, 1066 CX
- Attivo, non reclutante
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
-
Groningen, Olanda, 9713 GZ
- Attivo, non reclutante
- UMC Groningen
-
Nijmegen, Olanda, 6525 GA
- Attivo, non reclutante
- Stichting Radboud Universitair Medisch Centrum
-
Rotterdam, Olanda, 3015 GD
- Attivo, non reclutante
- Erasmus MC
-
-
-
-
-
Brzozów, Polonia, 36-200
- Attivo, non reclutante
- Szpital Specjalistyczny w Brzozowie
-
Bydgoszcz, Polonia, 85-796
- Ritirato
- Centrum Onkologii im. Prof. Franciszka Lukaszczyka
-
Gliwice, Polonia, 44-102
- Attivo, non reclutante
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, Oddzial Chemioterapii Dziennej
-
Warsaw, Polonia, 02-781
- Attivo, non reclutante
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
-
-
-
-
-
Cambridge, Regno Unito, CB2 0QQ
- Attivo, non reclutante
- Cambridge Addenbrooke's Hospital
-
Glasgow, Regno Unito, G12 0YN
- Ritirato
- Beatson, West of Scotland Cancer Centre
-
London, Regno Unito, NW1 2PG
- Attivo, non reclutante
- University College London Hospital
-
London, Regno Unito, SW3 6JJ
- Attivo, non reclutante
- Royal Marsden Hospital - Surrey
-
London, Regno Unito, SE1 9RT
- Ritirato
- Guy's Hospital
-
Manchester, Regno Unito, M20 4BX
- Attivo, non reclutante
- The Christie NHS Foundation Trust
-
Sheffield, Regno Unito, S10 2SJ
- Attivo, non reclutante
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
-
Barcelona, Spagna, 08035
- Attivo, non reclutante
- Hospital Universitario Vall d'Hebron
-
Barcelona, Spagna, 08041
- Ritirato
- Hospital de la Santa Creu i Sant Pau Barcelona
-
Barcelona, Spagna, 08908
- Attivo, non reclutante
- Institut Catala d'Oncologia - L'Hospitalet
-
El Palmar, Spagna, 30120
- Ritirato
- Hospital Clinico Universitario Virgen de la Arrixaca
-
Madrid, Spagna, 28041
- Attivo, non reclutante
- Hospital Universitario 12 de Octubre
-
Madrid, Spagna, 28040
- Attivo, non reclutante
- Hospital Clinico San Carlos
-
Madrid, Spagna, 28007
- Attivo, non reclutante
- Hospital General Universitario Gregorio Maranon
-
Madrid, Spagna, 28040
- Attivo, non reclutante
- Hospital Fundación Jiménez Díaz
-
Santiago de Compostela, Spagna, 15706
- Attivo, non reclutante
- Hospital Clinico Universitario de Santiago de Compostela
-
Seville, Spagna, 41013
- Attivo, non reclutante
- Hospital Universitario Virgen del Rocio
-
Zaragoza, Spagna, 50009
- Ritirato
- Hospital Universitario Miguel Servet
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35249
- Ritirato
- University of Alabama at Birmingham
-
-
Arizona
-
Scottsdale, Arizona, Stati Uniti, 85259
- Reclutamento
- Mayo Clinic
-
Tucson, Arizona, Stati Uniti, 85719
- Attivo, non reclutante
- University of Arizona- Cancer Center
-
-
California
-
Duarte, California, Stati Uniti, 91010
- Reclutamento
- City of Hope
-
Los Angeles, California, Stati Uniti, 90404
- Attivo, non reclutante
- University of California, Los Angeles (UCLA)
-
San Diego, California, Stati Uniti, 92093
- Reclutamento
- University of California, San Diego (UCSD)
-
San Francisco, California, Stati Uniti, 94158
- Attivo, non reclutante
- University of California, San Francisco
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80204
- Reclutamento
- University of Colorado Denver
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- Reclutamento
- MedStar Washington Hospital Center
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32224
- Reclutamento
- Mayo Clinic Jacksonville
-
Miami, Florida, Stati Uniti, 33136
- Reclutamento
- University of Miami - Sylvester Comprehensive Cancer Center
-
Orange City, Florida, Stati Uniti, 32763
- Ritirato
- Mid Florida Hematology and Oncology Center
-
Orlando, Florida, Stati Uniti, 32806
- Reclutamento
- Orlando Health Cancer Institute
-
Tampa, Florida, Stati Uniti, 33612
- Reclutamento
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Northwestern University
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- Reclutamento
- University of Iowa Hospital and Clinics
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160
- Attivo, non reclutante
- University of Kansas Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Reclutamento
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Reclutamento
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Reclutamento
- Mayo Clinic
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63130
- Reclutamento
- Washington University
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68114
- Reclutamento
- Nebraska Methodist Hospital
-
-
New York
-
Buffalo, New York, Stati Uniti, 14203
- Attivo, non reclutante
- Roswell Park Comprehensive Cancer Center
-
New York, New York, Stati Uniti, 10021
- Reclutamento
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27705
- Reclutamento
- Duke University
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44195
- Reclutamento
- The Cleveland Clinic Foundation
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- The Ohio State University Comprehensive Cancer Center
-
Toledo, Ohio, Stati Uniti, 43614
- Ritirato
- University of Toledo Medical Center
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Reclutamento
- Oregon Health & Science University (OHSU)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19111
- Reclutamento
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- Reclutamento
- University of Pittsburgh Medical Center - Hillman Cancer Center
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37920
- Ritirato
- University of Tennessee
-
Nashville, Tennessee, Stati Uniti, 37232
- Reclutamento
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030-4009
- Reclutamento
- The University of Texas MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Attivo, non reclutante
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53705
- Reclutamento
- University of Wisconsin - Carbone Cancer Center
-
-
-
-
-
Lund, Svezia, 22185
- Attivo, non reclutante
- Skane University Hospital Lund
-
Solna, Svezia, 171 76
- Attivo, non reclutante
- Karolinska University Hospital
-
-
-
-
-
Kaohsiung City, Taiwan, 83301
- Attivo, non reclutante
- Chang Gung Memorial Hospital - Kaohsiung Branch
-
New Taipei City, Taiwan, 10002
- Attivo, non reclutante
- National Taiwan University Hospital
-
Taichung, Taiwan, 40447
- Attivo, non reclutante
- China Medical University Hospital
-
Taipei, Taiwan, 11217
- Attivo, non reclutante
- Taipei Veterans General Hospital (VGHTP)
-
Taoyuan, Taiwan, 33305
- Attivo, non reclutante
- Chang Gung Memorial Hospital - Linkou Branch (CGMHLK)
-
-
-
-
-
Debrecen, Ungheria, 4032
- Attivo, non reclutante
- Debreceni Egyetem, Klinikai Központ, Onkológiai Klinika
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
-
Histologically confirmed locally advanced, metastatic, and/or unresectable GIST. Molecular pathology report must be available for Part 2; if molecular pathology report is unavailable or inadequate, an archival or fresh tumor tissue sample will be required to evaluate mutational status prior to randomization. (GIST 1L Substudy: must have documented mutation in KIT Exon 9 with an available molecular pathology report; archival or fresh tumor tissue sample will be required)
-
Documented disease progression on or intolerance to imatinib (Part 1a, Part 1b, Part 2, DDI Substudy)
-
Participants must have received the following treatment:
- DDI Substudy/Part 1a: Treatment with ≥1 prior lines of therapy for GIST
- Part 1b: Treatment with ≥2 prior TKI for GISTs
- Part 2: Prior treatment with imatinib only
- GIST 1L Substudy: No prior systemic therapy for GIST including adjuvant therapy. Exception: up to 10 participants with ongoing imatinib therapy of ≤4 weeks
-
Have at least 1 measurable lesion according to mRECIST v1.1 (Part1a, Part 1b, Part 2, GIST 1L Substudy)
-
Eastern Cooperative Oncology Group (ECOG) Status
- 0 to 2 (Part 1a, Part 1b, Part 2, DDI Substudy)
- 0 to 1 (GIST 1L Substudy)
-
Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits
Key Exclusion Criteria:
- Known Platelet-Derived Growth Factor Receptor (PDGFR) driving mutations or known succinate dehydrogenase deficiency (Part 1a, Part 1b, Part 2, DDI Substudy)
- Clinically significant cardiac disease
- Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug (Part 1a, Part 1b, Part 2, DDI Substudy)
- Gastrointestinal abnormalities including, but not limited to, significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption
- Any active bleeding excluding hemorrhoidal or gum bleeding
- Seropositive for HIV 1 or 2, or positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody.
- Active, uncontrolled, systemic bacterial, fungal, or viral infections at Screening
- Received strong CYP3A4 inhibitors or inducers (Part 1a, Part 1b, Part 2, DDI Substudy)
- Received sunitinib within 3 weeks (Part 1a, Part 1b, DDI Substudy)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Part 1a
Bezuclastinib plus sunitinib 37.5 mg once a day (QD) |
Participants will receive bezuclastinib orally until study stopping rules are met.
Altri nomi:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Altri nomi:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Altri nomi:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Altri nomi:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Sperimentale: Part 2 - Experimental Group
Bezuclastinib plus sunitinib 37.5 mg QD |
Participants will receive bezuclastinib orally until study stopping rules are met.
Altri nomi:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Altri nomi:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Altri nomi:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Altri nomi:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Comparatore attivo: Part 2 - Control Group
Sunitinib 37.5 mg QD |
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Sperimentale: Part 1b - DDI Cohort 1
Bezuclastinib plus sunitinib 37.5 mg QD |
Participants will receive bezuclastinib orally until study stopping rules are met.
Altri nomi:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Altri nomi:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Altri nomi:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Altri nomi:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Sperimentale: Part 1b - DDI Cohort 2
Sunitinib 37.5 mg QD plus bezuclastinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
Altri nomi:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Altri nomi:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Altri nomi:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Altri nomi:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Sperimentale: DDI Substudy (Midazolam)
Midazolam, bezuclastinib, sunitinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
Altri nomi:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Altri nomi:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Altri nomi:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Altri nomi:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. Participants will receive a single-dose of midazolam on Day 1 and Day 15 |
|
Sperimentale: GIST 1L Substudy
Bezuclastinib, sunitinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
Altri nomi:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Altri nomi:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Altri nomi:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Altri nomi:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Part 1a - pharmacokinetics - Cmax
Lasso di tempo: 16 days
|
Maximum plasma concentration (Cmax) |
16 days
|
|
Part 1a - pharmacokinetics - AUC
Lasso di tempo: 16 days
|
Area under the plasma concentration-time curve (AUC) |
16 days
|
|
Part 1b - pharmacokinetics - Cmax
Lasso di tempo: 14 days
|
Maximum plasma concentration (Cmax) |
14 days
|
|
Part 1b - pharmacokinetics - AUC
Lasso di tempo: 14 days
|
Area under the plasma concentration-time curve (AUC) |
14 days
|
|
Part 1b - pharmacokinetics - Tmax
Lasso di tempo: 14 days
|
Time to maximum observed plasma concentration (Tmax) |
14 days
|
|
Part 2 - Progression Free Survival (PFS)
Lasso di tempo: Approximately 48 months
|
Time from first dose to documented disease progression or death due to any cause, whichever occurs first |
Approximately 48 months
|
|
DDI Substudy - pharmacokinetics - AUC
Lasso di tempo: 16 days
|
Area under the plasma concentration-time curve (AUC) |
16 days
|
|
DDI Substudy - pharmacokinetics - Cmax
Lasso di tempo: 14 days
|
Maximum plasma concentration (Cmax) |
14 days
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
All Study Parts - observing the safety of each treatment regimen.
Lasso di tempo: Approximately 48 months
|
Incidence and severity of Adverse Events from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
Lasso di tempo: Approximately 48 months
|
Incidence and severity of Serious Adverse Events from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
Lasso di tempo: Approximately 48 months
|
Incidence of Adverse Events leading to dose modifications from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
Lasso di tempo: Approximately 48 months
|
Change from baseline in laboratory results |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Overall Survival (OS)
Lasso di tempo: Approximately 48 months
|
Time from first dose to death due to any cause |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Objective Response Rate (ORR)
Lasso di tempo: Approximately 48 months
|
Percentage of subjects who achieved documented complete response (CR) + confirmed partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Disease Control Rate (DCR)
Lasso di tempo: Approximately 48 months
|
Percentage of subjects who achieved CR + PR + stable disease (SD) at 16 weeks |
Approximately 48 months
|
|
Part 1a, Part 1b. Part 2 - Time to response (TTR)
Lasso di tempo: Approximately 48 months
|
Time from first dose to first documented response based on modified Response Evaluation Criteria in Solid Tumors Version 1.1 |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Duration of Response (DOR)
Lasso di tempo: Approximately 48 months
|
Time from first response (CR or PR) to the date of progression or death from any cause, whichever occurs first |
Approximately 48 months
|
|
Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30)
Lasso di tempo: Approximately 48 months
|
Change in individual scores in patients with locally advanced, unresectable, or metastatic GIST treated with CGT9486 in combination with sunitinib compared with patients treated with sunitinib monotherapy. The scale comprises 30 questions, 24 of which are aggregated into 9 multi-item scales, to include 5 functioning scales (physical, role, cognitive, emotional and social), 3 symptom scales (fatigue, pain and nausea/vomiting) and 1 global health status scale. The remaining 6 single-item scales assess symptoms (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning, while higher scores on the symptom and single-item scales indicate a higher level of symptoms. |
Approximately 48 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Processi neoplastici
- Neoplasie, Connettivo e Tessuto Molle
- Neoplasie, tessuto connettivo
- Condizioni patologiche, segni e sintomi
- Metastasi neoplastica
- Tumori stromali gastrointestinali
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Azoli
- Indoli
- Benzazepine
- Pirroli
- Benzodiazepine
- Sunitinib
- Midazolam
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CGT9486-21-301
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .